The women's health care product company reported a loss of 10 cents per share, which was in-line with analysts' forecasts. Revenue of $5.62 million was slightly higher than Wall Street's projections for revenue of $5.33 million.
In addition to posting solid quarterly results, TherapeuticsMD has a strong clinical pipeline of products, TheStreet's David Peltier said in a new Stocks Under $10article today. TherapeuticsMD is a holding of Peltier's Stocks Under $10 portfolio.
"TXMD has been knocked down along with the rest of the biotech sector, but we believe the company has several potential catalysts in its clinical pipeline that can drive the shares back into the double-digits in the coming quarters," Peltier wrote today.
TherapeuticsMD stock is down by 4.17% to $5.75 in midday trading on Friday.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.
You can view the full analysis from the report here: TXMD